U.S. Paper and Forestry Products Stock News

NYSE:FAF
NYSE:FAFInsurance

A Look At First American Financial (FAF) Valuation As Analyst Upgrades And Dividend Affirmation Draw Attention

Dividend affirmation and earnings momentum put First American Financial in focus First American Financial (FAF) has drawn fresh attention after analysts raised earnings estimates, which supports a top Zacks Rank #1 rating. The company also reaffirmed its quarterly cash dividend of $0.55 per share. See our latest analysis for First American Financial. At a share price of $68.16, First American Financial has seen steady momentum recently, including an 11.59% year to date share price return and...
NasdaqGS:FOXA
NasdaqGS:FOXAMedia

Did Softer Q3 Earnings and Heavy Buybacks Just Shift Fox’s (FOXA) Investment Narrative?

Earlier in May 2026, Fox Corporation reported fiscal third-quarter results showing sales of US$3,994 million and net income of US$166 million, while also disclosing that it has now repurchased 221,116,159 shares for about US$8.53 billions under its long-running buyback program. These results highlight a contrast between weaker reported earnings and management’s emphasis on resilient advertising trends, expanding distribution revenue, and growing contributions from digital platforms like Tubi...
NasdaqGS:JAZZ
NasdaqGS:JAZZPharmaceuticals

How Investors Are Reacting To Jazz Pharmaceuticals (JAZZ) Reaffirmed Guidance And Rare-Disease Portfolio Momentum

Jazz Pharmaceuticals recently reported a strong first quarter, citing solid commercial execution across its sleep, epilepsy, and oncology franchises, with key products Xywav, Epidiolex, Midevo, and Zepzelca driving revenue growth and management reaffirming full-year guidance while emphasizing rare disease expansion and financial readiness for potential acquisitions. For investors, the combination of double-digit growth across all promoted brands and a reiterated outlook highlights how Jazz’s...
NYSE:RHP
NYSE:RHPHotel and Resort REITs

Ryman Hospitality Properties (RHP) Valuation Check After Recent Share Price Momentum

Recent Performance Snapshot Ryman Hospitality Properties (RHP) has drawn attention after a recent share price move, with the stock last closing at US$110.99 and showing positive total returns over the past year and past 3 years. See our latest analysis for Ryman Hospitality Properties. The recent 1-month share price return of 6.38% and year to date share price return of 16.24% suggest building momentum. The 1-year and 3-year total shareholder returns of 23.18% and 41.16% point to a solid...
NasdaqGS:DMLP
NasdaqGS:DMLPOil and Gas

The Bull Case For Dorchester Minerals (DMLP) Could Change Following Strong Q1 2026 Royalty‑Driven Profit Gains

Dorchester Minerals, L.P. has reported past first‑quarter 2026 results, with sales of US$849,000, revenue of US$58.88 million and net income of US$28.26 million, all higher than a year earlier. The partnership’s earnings per unit rose to US$0.59, highlighting how its royalty and net‑profits interests can amplify benefits from stronger oil markets. We will now examine how Dorchester Minerals’ improved first‑quarter profitability, underpinned by higher royalty‑linked revenue, shapes its...
NYSE:CNC
NYSE:CNCHealthcare

How New Medicaid and Medicare Leadership at Centene (CNC) Has Changed Its Investment Story

At its Annual Meeting held on May 12, 2026, Centene appointed Daniel Finke as Group President of Medicaid and Marketplace and Michael Carson as Group President of Medicare and Specialty to oversee its core government and specialty businesses. These leadership appointments underline Centene’s effort to sharpen operational efficiency across Medicaid, Marketplace, Medicare and specialty lines, potentially influencing how it executes on its existing growth and margin recovery plans. We’ll now...
NasdaqGS:GH
NasdaqGS:GHHealthcare

Why Guardant Health (GH) Is Up 16.8% After Hiking 2026 Revenue Guidance on Shield Momentum

In early May 2026, Guardant Health reported first-quarter revenue of US$301.67 million versus US$203.47 million a year earlier, while its net loss widened to US$112.08 million and basic loss per share from continuing operations was US$0.85. On the same day, the company raised its 2026 revenue guidance to US$1.30–US$1.32 billion on the back of strong uptake for its FDA-approved Shield colorectal cancer screening test and broader oncology portfolio, underlining management’s confidence in the...
NasdaqGS:NWBI
NasdaqGS:NWBIBanks

A Look At Northwest Bancshares (NWBI) Valuation As Shares Hold Near Recent Levels

Northwest Bancshares (NWBI) has drawn investor attention after recent trading aligned with its solid one year and multi year total returns. This has prompted a closer look at how its regional banking business and current valuation fit together. See our latest analysis for Northwest Bancshares. Recent share price moves have been relatively steady, with the stock holding at around $13.66 after a modest 30 day share price return of 1.56%, while the 1 year and multi year total shareholder returns...
NasdaqGS:BANF
NasdaqGS:BANFBanks

Assessing BancFirst (BANF) Valuation As Options Activity Climbs And Earnings Beat Lifts Sentiment

Unusual options activity in BancFirst (BANF) has put the stock on many investors’ screens, with elevated implied volatility coinciding with a recent earnings beat and generally more positive analyst sentiment. See our latest analysis for BancFirst. Recent trading reflects this renewed attention, with the share price at $108.24 and a 1-year total shareholder return that declined 15.04%, while the 3-year and 5-year total shareholder returns of 31.34% and 77.84% point to a stronger longer term...
NasdaqGS:UFPI
NasdaqGS:UFPIBuilding

A Look At UFP Industries (UFPI) Valuation After Its Disappointing Quarterly Revenue And Earnings Results

UFP Industries (UFPI) is back in focus after its latest quarter showed declines in revenue and earnings per share, a miss versus analyst expectations that left the stock lagging other building materials peers. See our latest analysis for UFP Industries. The recent miss and weaker quarter have contributed to share price pressure, with UFP Industries’ 30 day share price return down 17.33% and its 1 year total shareholder return down 20.72%. This signals fading momentum despite slightly positive...
NasdaqGS:IPAR
NasdaqGS:IPARPersonal Products

A Look At Interparfums (IPAR) Valuation After Recent Auditor Change And Internal Control Weakness Disclosures

Interparfums (IPAR) has drawn fresh attention after its audit committee replaced Forvis Mazars with Grant Thornton as independent auditor. This move follows previously disclosed material weaknesses in internal controls over financial reporting. See our latest analysis for Interparfums. The auditor transition comes at a time when the share price has eased, with a 1 month share price return of 12.49% and a 3 month share price return of 14.48%, while the 1 year total shareholder return is down...
NasdaqGS:GILD
NasdaqGS:GILDBiotechs

How Investors May Respond To Gilead Sciences (GILD) Multi‑Billion Laddered Bond Issuance And Capital Plan

In May 2026, Gilead Sciences completed multiple fixed‑rate, callable senior unsecured bond offerings totaling about US$3.00 billion, with maturities from 2028 to 2034 and coupons ranging from 4.25% to 4.90%, supported by a broad syndicate of co‑lead underwriters including J.P. Morgan, Goldman Sachs, Morgan Stanley, and others. These financings, coming shortly after Gilead reported higher first‑quarter revenue and net income year on year and raised its 2026 product sales guidance, highlight...
NYSE:COTY
NYSE:COTYPersonal Products

Coty Lawsuits And CEO Exit Put Governance And Valuation In Focus

Multiple securities class action lawsuits have been filed against Coty (NYSE:COTY). The actions follow the abrupt departure of CEO Sue Y. Nabi and the withdrawal of Coty's 2026 financial guidance. Investors allege management made misleading statements about business conditions and softness in key segments. Coty operates in the global beauty and personal care industry, where brand strength, consumer trends, and distribution reach play a central role. For investors, management stability and...
NasdaqGS:MGRC
NasdaqGS:MGRCTrade Distributors

McGrath RentCorp’s Expanded Credit Line Raises a Key Question About Capital Discipline for MGRC

McGrath RentCorp recently completed a new US$725 million five-year credit facility maturing in 2031, replacing its prior US$650 million line of credit and earmarking the expanded capacity for working capital, capital expenditures and other general corporate uses. The upsized and extended facility, backed by a syndicate led by Bank of America with U.S. Bank and Wells Fargo, highlights lenders’ willingness to support McGrath RentCorp’s balance sheet flexibility and future investment...
NasdaqCM:MVST
NasdaqCM:MVSTMachinery

Assessing Microvast Holdings (MVST) Valuation After Weak First Quarter 2026 Earnings Results

What Microvast’s Latest Earnings Tell You Microvast Holdings (MVST) has drawn fresh attention after reporting first quarter 2026 results, with sales, net income and earnings per share all lower than a year earlier, sharpening the focus on the stock’s recent pullback. See our latest analysis for Microvast Holdings. The latest earnings report appears to have intensified existing pressure on Microvast’s share price. It is trading at US$1.20 after a 1-day share price return of down 4%, with the...
NasdaqGS:REG
NasdaqGS:REGRetail REITs

Is Regency Centers’ (REG) Updated Investor Pitch Quietly Reframing Its Retail Real Estate Strategy?

Earlier this month, Regency Centers Corporation’s Board declared quarterly cash dividends of US$0.390625 per share on its Series A preferred stock and US$0.367200 per share on its Series B preferred stock, both payable on July 31, 2026, to shareholders of record as of July 16, 2026. Alongside these preferred dividends, Regency Centers released an updated investor presentation outlining its strategic priorities and retail real estate positioning, aiming to reinforce confidence in its...
NasdaqGS:TYRA
NasdaqGS:TYRABiotechs

Assessing Tyra Biosciences (TYRA) Valuation After Wider Losses And Progress In Dabogratinib Trials

Tyra Biosciences (TYRA) stock is back in focus after first quarter results showed a wider net loss, a strong cash position, ongoing Phase 2 trials for dabogratinib and fresh institutional buying interest. See our latest analysis for Tyra Biosciences. The stock has cooled off in recent sessions, with the share price down 5.3% over the last day and 5.0% over the past month, but a 26.1% year to date share price return and a very strong 1 year total shareholder return of 238.5% point to momentum...
NasdaqCM:PLUG
NasdaqCM:PLUGElectrical

Plug Power’s UK Barrow Win Tests Strength Of Share Price Rebound

Plug Power has been selected to supply its GenEco PEM electrolyzer technology to the 30-megawatt Barrow Green Hydrogen project in the UK. The Barrow project is the first of three UK government supported hydrogen developments to reach final investment decision and move into execution. This contract marks a step in Plug Power's efforts to deploy its electrolyzer systems at scale in international markets. For investors watching NasdaqCM:PLUG, this contract sits against a share price of $3.31...
NasdaqGS:AAL
NasdaqGS:AALAirlines

American Airlines Centennial Puts CEO Plans And Policy Risks In Focus

American Airlines Group (NasdaqGS:AAL) is marking its 100th anniversary, highlighting a century of operations in U.S. and international air travel. The company’s CEO is scheduled to speak at a major industry strategy conference, where management is expected to discuss priorities for the next phase of the business. American Airlines is also publicly pushing back on proposed changes to U.S. airport security screening rules, arguing they could affect passenger experience and airline...
NYSE:EL
NYSE:ELPersonal Products

Is Estée Lauder (EL) Reframing Its Growth Story Around Emerging Markets And Digital Channels?

Earlier this year, Estée Lauder Companies’ CEO and a regional President spoke at the Morgan Stanley Luxury Conference 2026 in Paris, with the discussion made available via live and archived webcast for investors and other stakeholders. The conference appearance gave management a high-profile stage to articulate its thinking on emerging markets expansion and digital channels, areas already central to the company’s growth story. Next, we’ll examine how this executive appearance, particularly...
NasdaqGS:POWI
NasdaqGS:POWISemiconductor

How Softer Q1 Earnings and Steady Dividend Policy Could Shape Power Integrations’ (POWI) Investment Story

Earlier in May 2026, Power Integrations, Inc. reported first-quarter 2026 results showing sales of US$108.31 million and net income of US$3.3 million, while also declaring a quarterly dividend of US$0.215 per share payable on June 30, 2026 to shareholders of record on May 29, 2026. The combination of modest year-on-year sales growth, lower earnings, and continued dividend payments gives investors a clearer picture of how Power Integrations is balancing profitability pressures with ongoing...
NYSE:TDC
NYSE:TDCSoftware

Is Teradata (TDC) Still Attractively Priced After Strong One Year Share Price Rebound?

Wondering if Teradata at around US$32.65 is pricing in too much optimism or still offering value? This article walks through what the current numbers might be telling you. The stock has returned 2.9% over the past week, 20.5% over the past month, 10.0% year to date and 45.2% over the past year, while longer periods show declines of 27.0% over three years and 29.9% over five years. Recent headlines have focused on Teradata's role as a data and analytics platform provider, with attention on...
NYSE:POR
NYSE:PORElectric Utilities

Is It Too Late To Consider Portland General Electric (POR) After A 20% One-Year Gain?

Investors may be wondering whether Portland General Electric at around US$49.29 is offering good value right now, or if the recent gains have already been priced in. The stock is up 1.8% over the last week, has fallen 6.0% over the last month, and sits on a 20.5% return over the past year, which may signal shifting expectations around both its potential and its risks. Recent coverage around Portland General Electric has focused on its role as a regulated electric utility and how it fits into...
NYSE:DELL
NYSE:DELLTech

Assessing Whether Dell Technologies (DELL) Shares Look Mispriced After Their Strong Recent Run

Recent share performance and business scale Dell Technologies (DELL) stock has been active recently, with the price near US$235 and moves that include a gain of about 20% over the past month and a very large total return over the past 3 months. At a market value of roughly US$154.6b and annual revenue of about US$113.5b, Dell sits among the larger US tech companies, supported by both infrastructure and client-focused product segments. See our latest analysis for Dell Technologies. For...